| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Trade names | Pneucolin |
| Other names | DelNS1-nCoV-RBD LAIV[1] |
| Routes of administration | Intranasal |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
 COVID-19 portal |
DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine candidate developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.[2][3][4]
On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.[5]
References
- ^ "A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19". clinicaltrials.gov. United States National Library of Medicine. 29 April 2021. Retrieved 3 May 2021.
- ^ "China's nasal-spray COVID-19 vaccines undergoing clinical trials: official". Xinhua. 11 June 2021. Retrieved 10 July 2021.
- ^ "A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 7 April 2021. Retrieved 24 March 2021.
- ^ "A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 14 November 2020. Retrieved 24 March 2021.
- ^ "关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知" (in Chinese). National Health Commission. 14 December 2022. Retrieved 14 December 2022.
Scholia has a profile for DelNS1-2019-nCoV-RBD-OPT (Q106522065).
 | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 27 September 2023, at 06:22